Obesity Increases Tumor Aggressiveness in a Genetically Engineered Mouse Model of Serous Ovarian Cancer

Overview

Journal Gynecol Oncol

Date 2014 Apr 1

PMID 24680597

Citations 36

Authors

Liza Makowski

Chunxiao Zhou

Yan Zhong

Pei Fen Kuan

Cheng Fan

Brante P Sampey

Megan Difurio

Victoria L Bae-Jump

Affiliations

Soon will be listed here.

Abstract

Objectives: Obesity is associated with increased risk and worse outcomes for ovarian cancer. Thus, we examined the effects of obesity on ovarian cancer progression in a genetically engineered mouse model of serous ovarian cancer.

Methods: We utilized a unique serous ovarian cancer mouse model that specifically deletes the tumor suppressor genes, Brca1 and p53, and inactivates the retinoblastoma (Rb) proteins in adult ovarian surface epithelial cells, via injection of an adenoviral vector expressing Cre (AdCre) into the ovarian bursa cavity of adult female mice (KpB mouse model). KpB mice were subjected to a 60% calories-derived from fat in a high fat diet (HFD) versus 10% calories from fat in a low fat diet (LFD) to mimic diet-induced obesity. Tumors were isolated at 6 months after AdCre injection and evaluated histologically. Untargeted metabolomic and gene expression profiling was performed to assess differences in the ovarian tumors from obese versus non-obese KpB mice.

Results: At sacrifice, mice on the HFD (obese) were twice the weight of mice on the LFD (non-obese) (51g versus 31g, p=0.0003). Ovarian tumors were significantly larger in the obese versus non-obese mice (3.7cm(2) versus 1.2cm(2), p=0.0065). Gene expression and metabolomic profiling indicated statistically significant differences between the ovarian tumors from the obese versus non-obese mice, including metabolically relevant pathways.

Citing Articles

Clinically relevant body composition phenotypes are associated with distinct circulating cytokine and metabolomic milieus in epithelial ovarian cancer patients.

Davis E, Hsiao H, Barone N, Rosario S, Cannioto R Front Immunol. 2024; 15:1419257.

PMID: 39575261 PMC: 11578747. DOI: 10.3389/fimmu.2024.1419257.

Impact of Lifestyle Interventions on Gynecologic Cancers: Beyond Diet and Exercise.

McKenzie N, Ahmad S Am J Lifestyle Med. 2024; 18(1):7-20.

PMID: 39184272 PMC: 11339763. DOI: 10.1177/15598276221123764.

The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.

Davis E, Attwood K, Prunier J, Paragh G, Joseph J, Klein A J Natl Cancer Inst. 2024; 116(9):1513-1524.

PMID: 38802116 PMC: 11378317. DOI: 10.1093/jnci/djae112.

High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.

Baumann K, Siamakpour-Reihani S, Dottino J, Dai Y, Bentley R, Jiang C Gynecol Oncol. 2023; 179:97-105.

PMID: 37956617 PMC: 11510393. DOI: 10.1016/j.ygyno.2023.11.002.

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer.

Huang Y, Fan Y, Zhao Z, Zhang X, Tucker K, Staley A Int J Mol Sci. 2023; 24(15).

PMID: 37569750 PMC: 10418904. DOI: 10.3390/ijms241512375.

References

Engeland A, Bjorge T, Selmer R, Tverdal A . Height and body mass index in relation to total mortality. Epidemiology. 2003; 14(3):293-9. View

Van Dross R, Soliman E, Jha S, Johnson T, Mukhopadhyay S . Receptor-dependent and receptor-independent endocannabinoid signaling: a therapeutic target for regulation of cancer growth. Life Sci. 2012; 92(8-9):463-6. PMC: 4226396. DOI: 10.1016/j.lfs.2012.09.025. View

Lubin F, Chetrit A, Freedman L, Alfandary E, Fishler Y, Nitzan H . Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol. 2003; 157(2):113-20. DOI: 10.1093/aje/kwf184. View

Kong X, Tan B, Yin Y, Gao H, Li X, Jaeger L . L-Arginine stimulates the mTOR signaling pathway and protein synthesis in porcine trophectoderm cells. J Nutr Biochem. 2011; 23(9):1178-83. DOI: 10.1016/j.jnutbio.2011.06.012. View

Yakar S, Nunez N, Pennisi P, Brodt P, Sun H, Fallavollita L . Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology. 2006; 147(12):5826-34. DOI: 10.1210/en.2006-0311. View

Pavelka J, Brown R, Karlan B, Cass I, Leuchter R, Lagasse L . Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006; 107(7):1520-4. DOI: 10.1002/cncr.22194. View

Hosack D, Dennis Jr G, Sherman B, Lane H, Lempicki R . Identifying biological themes within lists of genes with EASE. Genome Biol. 2003; 4(10):R70. PMC: 328459. DOI: 10.1186/gb-2003-4-10-r70. View

Szabova L, Yin C, Bupp S, Guerin T, Schlomer J, Householder D . Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 2012; 72(16):4141-53. PMC: 3421072. DOI: 10.1158/0008-5472.CAN-11-3834. View

Khandekar M, Cohen P, Spiegelman B . Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011; 11(12):886-95. DOI: 10.1038/nrc3174. View

10.

Ford N, Dunlap S, Wheatley K, Hursting S . Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator microRNA-504. PLoS One. 2013; 8(6):e68089. PMC: 3696069. DOI: 10.1371/journal.pone.0068089. View

11.

Kamphorst J, Cross J, Fan J, de Stanchina E, Mathew R, White E . Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013; 110(22):8882-7. PMC: 3670379. DOI: 10.1073/pnas.1307237110. View

12.

Mohammad-Zadeh L, Moses L, Gwaltney-Brant S . Serotonin: a review. J Vet Pharmacol Ther. 2008; 31(3):187-99. DOI: 10.1111/j.1365-2885.2008.00944.x. View

13.

Pan L, Qiu Y, Chen T, Lin J, Chi Y, Su M . An optimized procedure for metabonomic analysis of rat liver tissue using gas chromatography/time-of-flight mass spectrometry. J Pharm Biomed Anal. 2010; 52(4):589-96. DOI: 10.1016/j.jpba.2010.01.046. View

14.

Liang C, Chen W, Zhi X, Ma T, Xia X, Liu H . Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Mol Cancer. 2013; 12:14. PMC: 3601970. DOI: 10.1186/1476-4598-12-14. View

15.

Yang H, Yoon C, Myung S, Park S . Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011; 21(9):1525-32. DOI: 10.1097/IGC.0b013e31822eb5f8. View

16.

Sobhia M, Grewal B, Ml S, Patel J, Kaur A, Haokip T . Protein kinase C inhibitors: a patent review (2008 - 2009). Expert Opin Ther Pat. 2013; 23(10):1297-315. DOI: 10.1517/13543776.2013.805205. View

17.

Olsen C, Green A, Whiteman D, Sadeghi S, Kolahdooz F, Webb P . Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007; 43(4):690-709. DOI: 10.1016/j.ejca.2006.11.010. View

18.

Rodriguez C, Calle E, Fakhrabadi-Shokoohi D, Jacobs E, Thun M . Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002; 11(9):822-8. View

19.

Leitzmann M, Koebnick C, Danforth K, Brinton L, Moore S, Hollenbeck A . Body mass index and risk of ovarian cancer. Cancer. 2009; 115(4):812-22. PMC: 3507338. DOI: 10.1002/cncr.24086. View

20.

Szydlowska M, Roszkowska A . Expression patterns of AMP-deaminase isozymes in human hepatocellular carcinoma (HCC). Mol Cell Biochem. 2008; 318(1-2):1-5. DOI: 10.1007/s11010-008-9773-x. View